Back to Search Start Over

Impact of comorbidities in the response of atopic patients treated with dupilumab: a real‐life study up to 36 weeks.

Authors :
Mastorino, L.
Cantafio Duò, V.L.
Vecco, C.
Gelato, F.
Giordano, S.
Roccuzzo, G.
Cavaliere, G.
Avallone, G.
Ortoncelli, M.
Ribero, S.
Quaglino, P.
Source :
Journal of the European Academy of Dermatology & Venereology. Dec2022, Vol. 36 Issue 12, pe1021-e1023. 3p.
Publication Year :
2022

Abstract

The atopic patient also suffers from non-allergic comorbidities whose impact on response to systemic treatments has rarely been evaluated in clinical practice.3 Among these, data on the impact of metabolic and psychiatric comorbidities in the response to dupilumab are scarce. Impact of comorbidities in the response of atopic patients treated with dupilumab: a real-life study up to 36 weeks 19 patients have no comorbidity at baseline vs. 22, this difference was not significant ( I P i = 0.5), similar results were observed when considering only patients with allergic comorbidities ( I P i = 0.22). [Extracted from the article]

Subjects

Subjects :
*DUPILUMAB
*ATOPY
*CLINICAL trials

Details

Language :
English
ISSN :
09269959
Volume :
36
Issue :
12
Database :
Academic Search Index
Journal :
Journal of the European Academy of Dermatology & Venereology
Publication Type :
Academic Journal
Accession number :
160200197
Full Text :
https://doi.org/10.1111/jdv.18427